Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Cromolyn Sodium in Locally Advanced Lung Cancer
NCT07675876Phase 1Not yet recruiting
- Sponsor
- CarcinEx
- Start
- Aug 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sodium cromoglycate in non-small cell lung cancer (NSCLC) and lung adenocarcinoma, sponsored by CarcinEx. Primary endpoint: Safety and Tolerability of Inhaled Cromolyn Sodium at 12 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sodium cromoglycate
03
Conditions
non-small cell lung cancer (NSCLC)lung adenocarcinoma
Beyond the preview
Go deeper on NCT07675876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07675876.